James M. Frates, Chief Financial Officer at Amylyx Pharmaceuticals, Inc. (AMLX), sold 3,326 shares at $11.11 ($37K) on 2026-01-06, disclosed to the SEC on 2026-01-08.
Seasonal sale ($37k) by Chief Financial Officer — this insider has traded AMLX in January in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| Filing → |
| AMLX | SELL | 2026-02-04 | $52K | — | Filing → |
| AMLX | SELL | 2025-10-02 | $309K | — | Filing → |
| AMLX | SELL | 2025-04-02 | $38K | — | Filing → |